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Liquid Biopsies in Cancer Diagnosis, monitoring and prognosis 16 
ABSTRACT 17 
Liquid biopsy, consisting in the non-invasive analysis of circulating tumor-derived material 18 
(the Tumor Circulome), represents an innovative tool in precision oncology to overcome 19 
current limitations associated with tissue biopsies. Within the tumor circulome, ctDNA and 20 
CTCs are the only components whose clinical application is FDA-cleared. Extracellular vesicles, 21 
ctRNA and tumor-educated platelets are relatively novel tumor circulome constituents with 22 
promising potential at each stage of cancer management. Here, we discuss the clinical 23 
applications of each element of the tumor circulome and the prevailing factors that currently 24 
limit implementation in clinical practice. We also detail the most recent technological 25 
developments in the field, which demonstrate potential in improving the clinical value of 26 
liquid biopsies. 27 
 28 
  29 
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Liquid Biopsies – Investigating the “Tumor Circulome”  30 
Cancer is one of the leading causes of death worldwide, with 8.8 million deaths estimated in 31 
2015i. In the USA, more than 1,735,350 cases of cancer are foreseen to be diagnosed in 2018, 32 
causing more than 609,640 deathsii. The development of “omics” technologies has led to the 33 
field of precision oncology that consists of tailoring treatment regimens to an individual’s 34 
tumor molecular characteristics [1]. The current golden standard for genetic profiling of 35 
tumors typically involves the use of tissue biopsies. Because of their invasive nature, tissue 36 
biopsies are associated with many limitations including patient risk, sample preparation, 37 
sensitivity (see Glossary) and accuracy, procedural costs and invasive testing.  This makes the 38 
procedure incompatible for clinical longitudinal monitoring [2]. Furthermore, a significant 39 
limitation of tissue biopsies is that they fail to capture intratumoral and intermetastatic 40 
genetic heterogeneity, impacting the accuracy of the test [3].  41 
Liquid biopsies present great potential in overcoming these existing sampling limitations.  42 
They consist of the sampling and analysis of liquid biological sources, typically blood, for 43 
cancer diagnosis, screening and prognosis. The “Tumor Circulome” , defined as the subset of 44 
circulating components is derived from cancer tissue andcan be directly or indirectly used as 45 
a source of cancer biomarkers in liquid biopsy [4]. These include: circulating tumor proteins, 46 
circulating tumor nucleic acids (ctDNA, ctRNA), circulating tumor cells (CTCs), tumor-derived 47 
extracellular vesicles (EV) , circulating tumor proteins and tumor-educated platelets (TEPs) 48 
(Figure 1, Key Figure). Liquid biopsies present several advantages over conventional tissue 49 
biopsies (see Table 1), and technological advancements in sample isolation (such as the 50 
development of nucleic acids extraction chips to minimize the manipulation of samples [5]) 51 
and detection platforms (such as the development of high resolution flow cytometers [6] or 52 
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single-cell Western Blot platforms [7]) are evolving to support this approach. The first 53 
important milestone in this field was reached in 2016 with the Food And Drug Administration 54 
(FDA) approval of the first companion diagnostic test for lung cancer based on the ctDNA 55 
content of a liquid biopsy [8].  56 
In this review, we detail the clinical significance and potential of liquid biopsies and provide 57 
an overview of recent reports supporting elements of the Tumor Circulome as biomarkers for 58 
the diagnosis and monitoring of cancer, with a particular focus on ctDNA, CTCs, tumor-derived 59 
EVs and ctRNAs. We also discuss factors limiting implementation in clinical practice and 60 
outline significant technological advances that may overcome these. Our focus will be on 61 
blood as the biological matrix for the liquid biopsy, however other biological fluids comprise 62 
a source of promising tumor-derived biomarkers too (see Box 1). 63 
 64 
Circulating Tumor-derived Proteins 65 
The measurement of circulating protein markers has historically been the gold standard 66 
approach used for the non-invasive diagnosis, screening and postoperative follow-up in 67 
cancer management. Notable examples of circulating tumor-derived protein markers include 68 
the  Prostate Specific Antigen (PSA) for prostate cancer screening [9] and CA 15-3 for 69 
postoperative follow-up of breast cancer recurrence [10]. These are compromised by high 70 
false positive rates, which can lead to overdiagnosis and in some cases unnecessary 71 
anticancer treatment [9].  In the case of CA 15-3, there are questions around its application 72 
in improvements in patient outcomes [10]. The use of panels or biosignatures comprised of 73 
more than one protein is a more promising approach, as the combination of multiple 74 
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biomarkers increases the diagnostic/prognostic capability of the assay by reducing the 75 
number of false positives and false negatives [11, 12].  76 
 77 
Circulating Tumor DNA (ctDNA) 78 
Circulating Tumor DNA comprises the fraction of circulating cell-free DNA (cfDNA) originating 79 
from cancer cells. This includes short nucleosome-associated fragments (80-200 bp) [13] and 80 
longer fragments (> 10 kb) encapsulated within EVs [14]. The mechanisms of ctDNA release 81 
into circulation include apoptosis, necrosis, lysis of CTCs and active secretion from the tumor 82 
[15]. The proof of the suitability of ctDNA as cancer biomarker came with the identification of 83 
KRAS gene mutations in ctDNA from the blood of pancreatic cancer patients [16].  84 
Clinical significance of ctDNA analysis 85 
Both qualitative and quantitative information can be obtained from ctDNA analysis 86 
[13].Quantitative information can be obtained from the measurement of the mutant allele 87 
fraction (MAF, the percentage of mutant allele in a given locus) and is a reflection of tumor 88 
burden [13]. It finds application in the detection of minimal residual disease (MRD) and 89 
occult metastases [17] and in the monitoring of treatment response and therapeutic 90 
effectiveness [18]. CtDNA levels provide a “real time” snapshot of tumor bulk because of its 91 
short half-life (around 2.5 hours) [13]. The detection of ctDNA after treatment is a high 92 
sensitivity and specificity predictor of relapse [19]. 93 
Qualitative information can be sourced through the profiling of mutations, 94 
duplications,amplifications, deletions and translocations in ctDNA (Figure 1), allowing the 95 
identification of genetic alterations associated with response, hence supporting decision-96 
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making for personalized management [13]. For example, the first ctDNA-based companion 97 
diagnostic test (cobas® EGFR Mutation Test v2 – Roche Diagnostics), recently approved by 98 
the FDA [8], is used to guide the use of Epidermal Growth Factor Receptor (EGFR)-Tyrosine 99 
Kinase Inhibitors on the basis of specific EGFR-sensitizing mutations in patients with non-100 
small cell lung cancer (NSCLC). Other qualitative information obtainable through ctDNA 101 
analysis includes assessment of methylation status. For example, a screening test for 102 
colorectal cancer, Epi proColon®, has been recently approved by FDA and analyzes the 103 
methylation pattern of the promoter of the SEPT9 gene, a region known to be 104 
hypermethylated in colorectal cancer when compared to normalnon-malignant samples [20]. 105 
Technological approaches and current limitations 106 
The currently available technologies for ctDNA analysis are based on polymerase chain 107 
reaction (PCR) or next-generation sequencing (NGS). Allele-specific PCR was the first 108 
approach used in ctDNA detection [16] and a quantitative PCR (qPCR) variation of this 109 
technique is currently adopted by the cobas® EGFR test [8]. Considering that the fraction of 110 
ctDNA in total cfDNA is usually very low, often less than 0.01% [21], more sensitive 111 
technologies have been developed and successfully used for ctDNA analysis, such as digital 112 
PCR (dPCR) [22], droplet digital PCR (ddPCR) [23] and Beads, Emulsion, Amplification, 113 
Magnetics (BEAMing) [24]. Although very sensitive, quick and relatively inexpensive, PCR-114 
based assays are limited by low multiplexing capacity, allowing for analysis of a restricted 115 
number of loci in parallel [13].  116 
The sensitivity of NGS-based technologies is lower than that of PCR-based technologies and 117 
inversely proportional to the number of loci analyzed, with Whole Exome Sequencing (WES) 118 
having the lowest sensitivity (≥5% MAF) [13]. Approaches to enhance the sensitivity of NGS 119 
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include considering patient- or cancer-specific gene panels, such as in the Cancer 120 
Personalized Profiling by deep Sequencing (CAPP-Seq) technology [25], or strategies to 121 
suppress the background noise generated by random errors occurring during library 122 
preparation. These strategies involve tagging each template molecule with Unique Molecular 123 
Identifiers (UMIs). These are used by different NGS platforms, such as eTAm-Seq™ (Enhanced 124 
Tagged Amplicon Sequencing) [26]. Another approach to enhance sensitivity includes the 125 
selective nuclease digestion of non-mutated DNA, which results in an increase in MAF and 126 
has enabled mutation detection down to 0.00003% MAF [27]. 127 
Despite its potential, the use of ctDNA as a liquid biopsy has many limitations. Detection 128 
sensitivity is a serious concern, especially in early cancer detection where the low amount of 129 
ctDNA may result in a MAF lower than the limit of detection of existing techniques [13]. The 130 
sampling of other body fluids, proximal to the putative site of the tumor, can increase the 131 
detection rate, at least in individuals at risk due to, for example, hereditary predisposition. 132 
This is mainly because, especially at early stages, a proximal body fluid may have a higher 133 
concentration of tumor-derived DNA than blood [28]. Another concern in early detection is 134 
the predictive value of single or small sets of mutations, as cancer-associated mutations can 135 
be found in plasma of healthy individuals as a result of clonal hematopoiesis [13]. One 136 
approach to overcome this challenge is to use the CancerSEEK platform, which associates the 137 
analysis of 8 tumor-derived proteins to ctDNA mutation profiling and has a specificity of >99% 138 
[29].  139 
Another limitation impeding the implementation of ctDNA analysis into clinical practice is the 140 
lack of standardized protocols for pre-analytical sample preparation and ctDNA purification. 141 
Current procedures are complex and may cause ctDNA degradation and blood cell lysis [30]. 142 
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A platform allowing a quick, single-step purification of ctDNA from blood is desirable, and lab-143 
on-a-chip systems have potential to address this need [5]. 144 
 145 
Circulating Tumor Cells (CTCs) 146 
CTCs are a population of tumor cells that have detached from the primary tumor and can be 147 
found in the peripheral blood of patients. Their presence is thought to be fundamental to the 148 
development of metastasis [31]. CTCs present systemically through active intravasation, with 149 
epithelial-to-mesenchymal (EMT) transition as a fundamental step [32], or through passive 150 
shedding from the primary tumor, . This latter a mechanism is supported by the  presence of 151 
CTC aggregates or Circulating Tumor Microemboli (CTMs) in the blood [33].  152 
Clinical significance of CTCs and analytical technologies 153 
The information that can be obtained from CTCs are quantitative as well as phenotypic 154 
(qualitative) through single cell genomic/transcriptomic/proteomic profiling (Figure 1). They 155 
have great potential as tools for diagnosis, monitoring, prognosis and prediction of response 156 
to therapy, and also for the discovery of novel drug targets [34]. Furthermore, the ex vivo 157 
culture of CTCs has an important translational value, because it allows to perform 158 
personalized drug sensitivity tests with the aim of basing treatment decision-making on 159 
evolving tumor mutational profiles and drug sensitivity patterns found in individual patients 160 
[35]. 161 
The simplest information obtainable from CTCs is their number, which is a prognostic 162 
predictor for many cancers including metastatic breast, colon and prostate cancers [36]. 163 
Currently the only FDA-cleared clinical application of CTCs is the CellSearch® platform used 164 
Formatted: Font: Bold
Commented [MK(24]: Potential Glossary term. 
Formatted: Font: Bold
Commented [GDR25R24]: Added to the Glossary 
Page 9 of 43 
 
for enumeration of epithelial  CTCs [36]. The power of CTC counts as a criterion for the 165 
selection of the first-line treatment in metastatic breast cancer is currently being investigated 166 
in the METABREAST trial (Clinical Trial Number: NCT01710605). 167 
With regards to the genetic and genomic information obtainable from CTCs, the technologies 168 
that can be used are similar to those of ctDNA analysis, and range from qPCR and dPCR-based 169 
mutational profiling to targeted NGS and whole genome sequencing [37]. Additionally, CTCs 170 
can be analyzed by cytogenetic analyses such as Fluorescence In Situ Hybridization (FISH) for 171 
the identification of chromosomal rearrangements [38]. NGS technologies have fundamental 172 
importance for single-CTC genomic and transcriptomic characterization, in the study of tumor 173 
heterogeneity and in comparative analysis with tissue biopsies [39]. Although the fields of 174 
single-cell genomics and transcriptomics have experienced significant developments, single-175 
CTC protein analysis is somewhat premature in comparison, with immunocytochemistry and 176 
flow cytometry being primarily used, both of which have poor multiplexing capacity.  New 177 
technologies are however emerging and Sinkala and colleagues recently developed a 178 
microfluidic-based single-cell Western Blot assay (scWB) which was used to assess the levels 179 
of 8 proteins in three metastatic cancer patient-derived single CTCs [7]. 180 
Despite numerous analytical platforms and technologies available for CTC analysis, their 181 
translation into clinical practice is limited by their isolation from blood. Challenges include 182 
their extreme rarity, fragility and physical and phenotypic heterogeneity [34]. Currently 183 
available strategies for CTC enrichment and isolation exploit their biological and physical 184 
properties, while functionality assays allow CTCs identification (Box 2 and Table 2). Each of 185 
these alternatives has advantages and drawbacks, and only their combination can support a 186 
comprehensive characterization. 187 
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 188 
Extracellular Vesicles (EVs) 189 
EVs are membranous particles released from all cell types in physiological and pathological 190 
conditions, as well as following different types of stimuli including proteases, ADP, thrombin,  191 
inflammatory cytokines, growth factors, biomechanical shear and stress inducers and 192 
apoptotic signals [40]. They can be found in almost every body fluid, especially in blood [41]. 193 
Once considered a simple means to eliminate unneeded cellular components from the 194 
cytoplasm of cells, during the last decade EVs have been recognized as fundamental 195 
mediators of intercellular communication, regulating and participating to a plethora of 196 
physiological and pathological processes including cancer [41].  Based on their biogenesis, 197 
content and secretory pathways, EVs can be divided into two broad categories: exosomes and 198 
microvesicles [41]. 199 
Clinical significance of EVs as cancer biomarkers 200 
The suitability of EVs as cancer biomarkers lies in the fact that the molecular cargo they carry 201 
can be considered a molecular fingerprint of the cell of origin [42]. Compared to ctDNA and 202 
CTCs, whose implementation in clinical cancer diagnostics is hampered by challenges in their 203 
isolation, analytical sensitivity and by stability concerns, the potential advantages of EVs are 204 
many. EVs are typically produced and released in abundant quantities and in greater amounts 205 
compared to  CTCs [43]. Likewise, the stability of the vesicular cargo is maintained through a 206 
protecting  outer lipid membrane [44]. 207 
Similarly to ctDNA and CTCs, EVs can be source of quantitative and qualitative information. 208 
Quantitative information comprising EVs numbers can inform the presence of malignant 209 
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disease and tumor burden. For example, circulating exosome levels are increased in breast 210 
and pancreatic cancer [45] and the number of circulating microparticles (MPs) is higher in 211 
multiple myeloma (MM) patients compared to healthy individuals [46]. Furthermore, 212 
circulating MP levels demonstrated potential for the diagnosis and prognosis of advanced 213 
NSCLC [47]. 214 
Qualitative information through the molecular characterization of EV constituents, including 215 
nucleic acids and proteins (Figure 1) , are the most readily obtained (Figure 1) [42]. The RNA 216 
content of EVs, including both coding and non-coding RNAs, has been widely studied [43] . 217 
The DNA content of exosomes has recently gained attention as a biomarkers source in a study 218 
in which mutations in KRAS and TP53 have been detected in serum exosomes from pancreatic 219 
cancer patients [14]. In another study, the identification of exosomal KRAS mutations proved 220 
better than CA 19-9 for prognostic stratification of patients with pancreatic ductal 221 
adenocarcinoma (PDAC) [48].  222 
EVs carry proteins in their lumen and in their membrane, and numerous reports have been 223 
published demonstrating the important role of EV proteins as possible cancer biomarkers 224 
[42]. Melo et al. demonstrated the ability of circulating exosomal Glypican-1 (GPC1) to 225 
distinguish PDAC from healthy donor samples with a reported accuracy of 100% [45]. More 226 
recently, Moon et al. demonstrated the suitability of EV Del-1 [49] and Fibronectin [50] as 227 
biomarkers for early breast cancer diagnosis. Furthermore, our group demonstrated that the 228 
levels of circulating CD138+ MPs increase in MM and observed a significant prognostic 229 
potential for CD138+ MPs in predicting risk of relapse and therapeutic response in individual 230 
patients [46]. Finally, the levels of AnnexinV+ EpCAM+ Asialoglycoprotein Receptor-1 231 
(ASGPR1)+ circulating MPs are diagnostic of hepatocellular carcinoma and 232 
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cholangiocarcinoma [51], and the levels of CD147+ EpCAM+ MPs are predictors of colorectal 233 
carcinoma [52]. 234 
Technologies for EVs isolation and analysis and recent advances 235 
One important limitation to the clinical application of EVs as liquid biopsy is the lack of 236 
standardized protocols for sample handling and EV isolation and analysis, which could impact 237 
reproducibility in the clinical setting [53]. Currently used EV isolation procedures often consist 238 
of many biospecimen handling steps and can subject EVs to different types of physical and 239 
chemical insults, which may damage EVs and/or modify their biological and physical 240 
properties. Another factor influencing the reproducibility of EV studies is the lack of 241 
standardized guidelines defining EVs nomenclature and definition, and the control 242 
experiments needed for validation. In order to overcome these limitations, a comprehensive 243 
collection of guidelines and recommendations has been very recently updated by the 244 
International Society for Extracellular Vesicles [54]. 245 
Similarly to CTCs, conventional EVs isolation strategies exploit physical (density, size) and 246 
biological (expression of surface markers) properties [55]. Density-based approaches, such as 247 
differential centrifugation/ultracentrifugation and density gradient centrifugation, are the 248 
most commonly used methods for EV isolation. Among these, differential ultracentrifugation 249 
is considered the gold-standard technique, especially for exosome purification. Although 250 
widely used, these techniques rely on expensive equipments, are time-consuming and don’t 251 
guarantee pure yields, often resulting in a compromise between purity and recovery [55]. 252 
Size-based techniques include filtration and size exclusion chromatography (SEC). Filtration 253 
can result in high yields and purity, but again is limited in terms of EVs adherence to the filters 254 
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and vesicle damage due to high pressure [56]. SEC allows a superior recovery of EVs compared 255 
to ultracentrifugation [56]. 256 
Immunoaffinity capture methods use magnetic beads conjugated to antibodies recognizing 257 
EV surface markers. An advantage of these methods is that they produce EV fractions with 258 
high purity, allowing the isolation of specific subsets of EVs based on the surface marker used. 259 
This feature, on the other hand, could be a limitation because it may overlook potentially 260 
important EV subpopulations lacking the expression of the selected marker [55]. A novel 261 
development of immunoaffinity capture is its integration into microchips allowing in-situ 262 
immunoassay analysis [57].  263 
Another commonly used isolation method, especially for exosomes, is polymer precipitation. 264 
This method involves the use of polymers (such as polyethylene glycol (PEG)) to reduce the 265 
solubility of EVs, in order to precipitate them with a rapid low-speed centrifugation. Although 266 
producing high recovery rates, this methodology has low purity [58]. 267 
Recently emerging methodologies for EV isolation use electric fields. Lewis et al. developed 268 
an Alternating Current Electrokinetic (ACE) Chip capable of performing exosome capture from 269 
whole blood and in-situ immunofluorescent analysis in 30 minutes. They validated this chip 270 
by assessing the suitability of GPC-1 and CD63 levels as diagnostic markers of PDAC [59]. 271 
Finally, another promising category of potential novel approaches to EV isolation relies on 272 
microfluidics [58]. The available microfluidic approaches are based on different EV properties, 273 
eg: nanoscale size-based filtration [60], antibody-functionalized microfluidic channels [61] 274 
and spiral inertial microfluidic devices [62]. In a recent report, Ko et al. developed a magnetic 275 
nanopore sorting platform that has been used to isolate specific cancer-derived EVs. They 276 
used this system to identify, in a mouse model of PDAC, a miRNA signature to train a machine 277 
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learning algorithm for the classification of distinct cancer states [63]. Microfluidics 278 
technologies are set to boost the development of lab-on-a-chip systems for fast, cost-279 
effective, integrated isolation and analysis of EVs, towards the development of EV-based 280 
point-of-care diagnostics.  281 
Together with the isolation methods, EV detection methods are also experiencing advances 282 
in development, especially with regards to the analysis of protein cargo. Common analytical 283 
technologies include Western blot (WB), Enzyme-linked immunosorbent assay (ELISA), mass 284 
spectrometry (MS) and flow cytometry (FCM) [64]. With the exception of FCM, these 285 
techniques focus primarily on bulk EV analysis, without assessing their individual variability 286 
[58]. FCM is currently used for single-MPs characterization [46, 51, 52], but fails to analyze 287 
single exosomes due to their small size. Exosome FCM analysis currently involves the binding 288 
of multiple exosomes to larger beads [45]. Recently, Kibria et al. developed a microFCM 289 
platform which was capable of assessing the expression of CD47 in single circulating 290 
exosomes from breast cancer patients [6]. Another technique capable of allowing single-EV 291 
protein phenotyping, at a higher size resolution than current flow cytometers, is a variation 292 
of Nanoparticle Tracking Analysis (NTA) in which fluorescent antibodies are used to identify 293 
EVs expressing a given marker [65]. Despite better size resolution of NTA, a great advantage 294 
of FCM is its higher multiplexing capacity. 295 
 296 
Circulating Tumor RNA (ctRNA) 297 
The fraction of circulating cell-free RNA originating from cancer cells is referred to as 298 
circulating tumor RNA (ctRNA). The existence of extracellular RNA was first documented in 299 
1978 [66] and the first report about its potential as cancer biomarkers was shown years later 300 
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[67]. Compared to DNA, RNA is a relatively unstable molecule, whose naked half-life in plasma 301 
is approximately 15 seconds [68]. Its stability is enhanced by its association with proteins [69], 302 
proteolipid complexes [67] and extracellular vesicles [44]. 303 
Clinical significance of ctRNA as cancer biomarker and current limitations 304 
Nearly all known classes of RNA have been found in systemic circulation and, to a certain 305 
extent, each one of them has potential to serve as cancer biomarkers [70]. Similar to other 306 
components of the tumor circulome, ctRNA is source of quantitative and qualitative 307 
information. In fact, although expression profiles of coding and non-coding RNAs (ncRNAs) 308 
represent the most important source of information, the identification of tumor-specific 309 
fusion transcripts or alternative splice events is also possible [71]. The most important classes 310 
of ctRNA potentially suitable as biomarkers are mRNAs, miRNAs and long non-coding RNAs 311 
(lncRNAs) (Figure 1). Their analysis is performed with techniques ranging from qRT-PCR or 312 
dPCR-based assessment of single or small panels of RNAs to the comprehensive 313 
characterization of RNAs (especially miRNAs) signatures via RNA-Seq [70]. 314 
Circulating exosomal mRNA has been used to investigate the mutational status of KRAS and 315 
BRAF in patients with colorectal cancer (CRC) [72], and exosomal EGFRvIII mRNA has potential 316 
for the diagnosis of EGFRvIII-positive high-grade gliomas [73]. In another report, the detection 317 
of androgen receptor splice variant 7 (AR-V7) in plasmatic exosomes by ddPCR has been 318 
shown to be a good predictor of resistance to hormonal therapy in prostate cancer [74]. 319 
Numerous lung cancer-related gene fusions are also readily identified in both vesicular and 320 
non-vesicular mRNA and have value as biomarkers [75]. Among the non-vesicular fraction of 321 
ctRNAs, circulating human Telomerase Reverse Transcriptase (hTERT, catalytic subunit of the 322 
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Telomerase Complex) mRNA has demonstrated a greater diagnostic and prognostic accuracy 323 
than PSA for prostate cancer [76]. 324 
With regards to miRNAs, plasma exosomal miR-196a and miR-1246 levels have potential for 325 
the early diagnosis of pancreatic cancers [77], and panels of miRNAs have been shown to be 326 
reliable biomarkers for diagnosis [78] or prognosis [79] of lung cancer. More recently, a serum 327 
exosomal miRNA signature has proven to be an innovative tool for the differential diagnosis 328 
of gliomas [80].  329 
A novel promising source of RNA biomarkers are long-noncoding RNAs (lncRNAs). For 330 
example, plasma exosome LINC00152 levels have been linked to gastric cancer [81], and the 331 
combination between two mRNAs and one lncRNA in serum exosomes has diagnostic 332 
potential for colorectal cancer [82]. Furthermore, serum exosomal HOTAIR lncRNA has 333 
applicability in diagnosis and prognosis of glioblastoma multiforme [83]. More recently, a 334 
panel of five circulating lncRNAs has been studied as a promising diagnostic biomarker for 335 
gastric cancer [84]. 336 
To date, the most important limitations for the implementation of ctRNAs in the clinical 337 
setting involve the pre-analytical and analytical steps. Although circulating RNAs are 338 
protected by the association with different molecules and structures, they are unstable in 339 
plasma if stored at 4°C, and limited by the speed of extraction [85]. Furthermore, different 340 
extraction protocols have different recovery rates, and there is currently no consensus on an 341 
optimal extraction protocol [85]. Again, lab-on-a-chip devices seem to offer a potential 342 
solution to this issue, allowing rapid and integrated purification and analysis of samples while 343 
minimizing their handling. A proof-of-concept of this is the microdevice developed by Potrich 344 
et al., which is capable of selectively extracting miRNAs from cell culture supernatant and 345 
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allows in situ reverse transcription and qPCR analysis [86]. Another example is the Integrated 346 
Comprehensive Droplet Digital Detection (IC 3D) system, a microfluidic platform capable of 347 
quantifying extremely low concentrations of miRNAs directly from plasma in 3 hours [87]. 348 
 349 
Tumor-Educated Platelets (TEPs) 350 
TEPs are perhaps the latest components of the tumor circulome to be considered for 351 
biomarker analysis. The concept of “platelet education” by cancer refers to the presence of 352 
specific RNA signatures in platelets of cancer patients. This was first reported in 2010 and 353 
2011 with the observations that: in metastatic lung cancer patients, 197 platelet genes were 354 
downregulated and several genes were differentially spliced compared to non-cancer 355 
controls [88]; in glioma, cancer-derived microvesicles are actively taken up by platelets and 356 
transfer their RNA content, harboring a cancer-characteristic RNA signature revealed by 357 
microarray [89]. Best et al. in 2015 characterized TEPs extracted from a patient cohort across 358 
6 cancer types via RNA-Seq, distinguishing patients with localized or metastatic tumor from 359 
healthy individuals with 96% accuracy and locating the anatomical position of the tumor with 360 
71% accuracy. This paved the way for “pan-cancer and multiclass cancer diagnostics” [90]. In 361 
more recent work, the same group applied Particle-Swarm Optimization (PSO)-enhanced 362 
algorithms swarm intelligence-enhanced algorithms to platelet RNA-Seq libraries to generate 363 
a panel of biomarkers capable of distinguishing lung cancer patients from healthy individuals 364 
and from those with lung inflammatory conditions [91].  365 
 366 
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TEPs is minimally described and tumor proteins are not (reference Fig1 ). Is there a way to put 367 
these too classes in better context with the Figure? So that readers can follow Fig.1 and text 368 
better? In this current draft…I feel that it seems that the authors abruptly ended TEPs and 369 
forgot about tumor proteins. Some explanation is required. 370 
Controversies on the use of Liquid Biopsies in cancer management 371 
Despite reports demonstrating potential of liquid biopsies in addressing the current 372 
needs in cancer management, numerous controversies remain on their utility. This is 373 
particularly true for ctDNA and CTCs, which have already found application in clinical 374 
management.  In a recent report Torga et al. [92] compared the performance of two 375 
commercially available NGS-based ctDNA tests for metastatic prostate cancer, finding an 376 
astonishingly low concordance (7.5% patients studied) between the two tests. The 377 
discordance was attributed to issues in study design and sample analysis, raising current 378 
limitations of preanalytical and analytical standardization in the field. Furthermore, with very 379 
few exceptions, most of the ctDNA assays available have limited evidence of clinical validity 380 
and utility in advanced cancer. Likewise, their utility in early-stage cancers, treatment 381 
monitoring or MRD detection remains to be established [93]. Additionally, with regards to 382 
CTCs, although their clinical validity has been demonstrated, particularly for their prognostic 383 
capacity in metastatic disease, evidence of their clinical utility is still missing,  preventing their 384 
implementation into standard clinical practice [94]. Numerous large-scale clinical trials are 385 
clearly needed, and some are currently in progress to address this unmet need.   386 
 387 
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Current standards for patient stratification and treatment selection include the analysis of 389 
tumor genetic alterations from tissue biopsies. Despite their undoubted value, tissue biopsies 390 
have important limitations, being highly invasive procedures that fail to capture tumor clonal 391 
heterogeneity. Liquid biopsies, consisting in the analysis of circulating tumor-derived factors 392 
(the Tumor Circulome), are gaining exceptional attention as a valuable alternative. The tumor 393 
circulome is source of different classes of tumor-derived biological components. Novel 394 
technologies are being developed to further improve the analysis of the tumor circulome, 395 
with the aim of fully exploring the complexity of the information obtainable from a simple 396 
blood draw. 397 
The studies reviewed here underline the tremendous potential of liquid biopsies, and the 398 
development of novel technologies allows researchers to characterize each single component 399 
of the tumor circulome with increasing precision. Liquid Biopsies are being positioned as a 400 
game-changing tool in personalized cancer management. However, their clinical application 401 
has been comparatively slow, hampered by multiple technical challenges (listed in Table 3). 402 
As a consequence, several problems still need to be resolved to firmly establish the role of 403 
liquid biopsies in the clinical setting (see Outstanding Questions). The lack of standardization 404 
of pre-analytical and analytical variables is a significant limitation in the field. A liquid biopsy 405 
ideally should be cost effective, fast, reproducible and ensure sample integrity. One approach 406 
via which this can be achieved is through automated chip-based devices allowing for the 407 
analysis of biomarkers from whole blood without the need for lengthy and costly purification 408 
steps.  While complex chip systems such as the ACE chip remain costly, alternative polymeric 409 
microfluidic devices such as the spiral microfluidic chip used for CTC isolation are, in 410 
comparison, cost effective [95]. Although much work is still needed to comprehensively define 411 
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the future role of liquid biopsies in cancer diagnosis, monitoring and prognosis, the promising 412 
results reported so far testify to the potential of this approach in changing the current 413 
paradigms of cancer management. 414 
  415 
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TEXT BOXES 416 
Box 1 – Liquid biopsy of othernon-blood  biological specimens body fluids biological 417 
specimens different from other than blood 418 
Although the “standard” concept of liquid biopsy consists in the sampling of blood, virtually 419 
all body fluids are suitable as liquid biopsy. The anatomic localization of primary or metastatic 420 
tumors influences the presence of tumor-derived material in the corresponding body fluids. 421 
Common body fluids  include urine, saliva, sputum, stool, cerebrospinal fluid (CSF) and pleural 422 
effusions. Many of these have demonstrated great potential as a source of cancer biomarkers 423 
[96, 97]. 424 
Urine: Urine is a valuable source of ctDNA for  urogenital cancers such as prostate, bladder 425 
and cervical cancers  and non-urogenital malignancies such as NSCLC, Colorectal Cancer (CRC) 426 
and gastric cancer [98], and its EV content is source of several candidate biomarkers [99]. The 427 
first liquid biopsy test on urine, Progensa® PCA3 Assay was, FDA approved in 2012iiito aid the 428 
decision-making of a repeat prostate biopsy in case of a first negative biopsy. This test 429 
measures the level of Prostate Cancer Antigen 3 (PCA3) lncRNA, which is increased ini more 430 
overthan 95% of primary prostate tumors [100]. Another promising urine-based test is the 431 
ExoDx® Prostate(IntelliScore)iv, a Laboratory-Developed Test (LDT) based on the analysis of 432 
the levels of three exosome-associated RNAs overexpressed in high-grade prostate cancer 433 
which is used to “rule-out” potentially unnecessary prostate biopsies. 434 
Saliva: Salivary biomarkers include ctDNA for head and neck squamous cell carcinoma [101], 435 
and microRNAs (miRNAs) for detecting early malignancy in potentially malignant oral  cancers 436 
Commented [MK(36]: Please provide full forms here. 
Thank you. 
Commented [GDR37R36]: Done. NSCLC is defined in full 
form in the main text 
Commented [MB38]: Expression relates to proteins not 
nucleic acids.  Find another term 
Commented [GDR39R38]: Done 
Commented [MK(40]: Please insert full form. Also, please 
explain here briefly how PCA3 lncRNA levels are helpful in 
prostrate cancer diagnosis….goes up?goes down? Presence 
shows something? 
Commented [GDR41R40]: done 
Formatted: Font: Bold
Commented [MK(42]: Please clarify the meaning? 
Commented [GDR43R42]: Described in the Glossary with 
the FDA definition 
Commented [MK(44]: Please clarify if presence/absence 
tells results….this sentence comes off as little vague. 
Commented [GDR45R44]: done 
Page 22 of 43 
 
[102]. Furthermore, EV-associated miRNAs have the potential to be used as biomarkers of 437 
oral squamous cell carcinoma [103]. 438 
CSF: CSF, thanks to its direct contact with the central nervous system (CNS), is set to become 439 
an important source of biomarkers for CNS-restricted cancers, potentially overcoming the 440 
relative scarcity of circulating biomarkers (especially ctDNA) in these diseases caused by the 441 
blood-brain-barrier [104]. CSF-derived ctDNA has proven to represent genetic alterations of 442 
brain tumors better than plasma ctDNA [105], and a miRNA CSF signature for glioblastoma 443 
has been recently reported [106]. 444 
Other bodily fluids: The analysis of stool-derived DNA has been recently validated as a 445 
powerful diagnostic tool for colorectal cancer [107], while sputum DNA and protein content 446 
has promising potential in the context of lung cancer [108]. Pleural effusions, finally, are 447 
source of DNA biomarkers for lung cancer [109] and malignant pleural mesothelioma [110], 448 
and the presence of Epithelial Cell Adhesion Molecule (EpCAM)+ microparticles allows 449 
distinction between malignant and non-malignant pleural effusions [111]. 450 
The studies reported here are examples of the enormous potential of non-blood liquid 451 
biopsies as biomarkers trove. The association between information obtained from blood and 452 
non-blood samplings will surely represent a precious added value in the field of liquid biopsy. 453 
 454 
Box 2 - Strategies for CTC isolation, enrichment and identification  455 
Based on biological properties: Approaches based on biological properties of CTCs exploit the 456 
expression of cell surface markers for their isolation and selection [34]. The most used marker 457 
for positive selection is EpCAM, which is a calcium-dependent transmembrane glycoprotein 458 
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that mediates cell adhesion in epithelia and is, detected by the CellSearch® platform [36]. 459 
CellSearch® integrates immunomagnetic enrichment of EpCAM+ cells and staining with anti-460 
cytokeratine (CK), anti-CD45 and DAPI [36]. A limitation of EpCAM-dependent approaches is 461 
that many CTCs don’t express EpCAM  as they undergo Epithelial-to-Mesenchimal Transition 462 
(EMT), thus underestimating CTC counts [112]. To overcome this, other markers must be 463 
considered. For example, Gao and colleagues enriched lung cancer CTCs using anti-EpCAM, 464 
anti-Mucin 1(MUC1) and anti-EGFR antibodies [113]. Alternative approaches, preferable 465 
because they include EpCAMlow and EpCAM- populations, leaving CTCs unstained, involve the 466 
immunomagnetic depletion of CD45+ leukocytes [114]. Other EpCAM-based strategies 467 
include microfluidic platforms such as the CTC-Chip [115] and the NanoVelcro system [116], 468 
and devices for the in vivo capture of CTCs directly into patients’ veins, such as the GmbH 469 
CellCollector device [117]. 470 
Based on physical properties: Other enrichment technologies exploit CTCs’ physical 471 
properties. CTC isolation by size is possible as CTCs are generally larger than leukocytes [118]. 472 
Size-based approaches include filtration methods, such as the Isolation by Size of Tumor cells 473 
(ISET®) [118] and Metacell® [119] devices. Limitations of filtration include difficulty of 474 
detaching cells from the filter and loss of cell viability [37]. To overcome these, label-free 475 
microfluidics devices were developed, such as Parsortix™[120]. More recently, CellSearch® 476 
and Parsortix™ were sequentially combined to separately isolate EpCAM+ and EpCAMlow/- 477 
CTCs from blood of metastatic breast cancer patients, simultaneously analyzing the matched 478 
CTC populations [121]. Another example of size- based CTC enrichment is the high-throughput 479 
spiral inertial microfluidic biochip, which has been clinically validated in breast and lung 480 
cancer [122]. 481 
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Technologies exploiting density include differential centrifugation [123] and platforms 482 
such as MagDense [124]. Other technologies involve exploiting the differences between 483 
dielectric properties of CTCs and white blood cells (WBCs) and form the basis of  484 
Dielectrophoresis (DEP)-based platforms [125]. DEP can behas been associated with Lateral 485 
Field Flow Fractionation (LFFF)  to improve the isolation of spiked breast cancer cells from 486 
regular blood cells [126]. A similar technology is the DEPArray, a microfluidics platform that 487 
combines DEP and imaging and has been used to accurately sort single breast cancer cells 488 
following CellSearch® enrichment [127].  489 
CTC functional assays support CTCs identification based on functional characteristics, 490 
overcoming limitations attributed to their heterogeneity. The Vita-Assay™ exploits the ability 491 
of CTCs to digest a Cell Adhesion Matrix (CAM), measuring the uptake of CAM proteins on a 492 
coated culture dish via fluorescence. [128]. The EPISPOT Assay detects viable CTCs through 493 
detection of specific proteins released following culture on substrates functionalized with 494 
specific antibodies [129]. The TelomeScan® platform exploits the activation of telomerase in 495 
most cancers, allowing identification of CTCs by using adenoviruses that selectively replicate 496 
in cells expressing functional hTERT, expressing GFP [130]. 497 
  498 
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Table 1 – Advantages of Liquid Biopsies over conventional Tissue Biopsies 499 
 Tissue Biopsy Liquid Biopsy 
Invasiveness High Minimal 
Pain Yes No 
Risk of complications Yes No 
Time needed Time-consuming Quick 
Tumor heterogeneity 
representation 
Low/null High/total 
Tumor region selection 
bias 
Yes No 
Compatibility with 
longitudinal monitoring 
No Yes 
  500 
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Table 2 – Examples of CTCs isolation, enrichment and identification strategies 501 
Category Principle Technique / Platform Ref. 
Biological 
Properties 
Surface marker 
expression 
EpCAM+ Enrichment / 
CellSearch® 
[36] 
EpCAM+ + other surface 
markers 
[113] 
CD45+ Depletion [114] 
GmbH Cell Collector (in vivo 
capture) 
[117] 
Surface marker 
expression - 
Microfluidics 
CTC-Chip [115] 
NanoVelcro [116] 
Physical Properties Size - Filtration ISET® [118] 
Metacell® [119] 
Size - Microfluidics Parsortix™ [120] 
Spiral inertial microfluidic 
chip 
[122] 
Density Differential Centrifugation [123] 
MagDense [124] 
Dielectric Properties DEP [125] 
DEP-LFFF [126] 
DEPArray [127] 
 Functional Assays CAM digestion Vita-Assay™ [128] 
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Protein Release during 
Culture 
EPISPOT Assay [129] 
Telomerase Expression TelomeScan® [130] 
  502 
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Table 3 – Limitations of Liquid Biopsies  503 
Liquid Biopsy 
Component 
Limitations Solutions Ref. 
Circulating Tumor 
DNA (ctDNA) 
Low Sensitivity of 
mutation detection 
(when MAF is low) 
Unique Molecular 
Identifiers 
Nuclease digestion of 
non-mutated DNA 
Sampling of alternative 
body fluids 
[26] 
 
[27] 
[28] 
Low predictive value of 
single / small sets of 
mutations 
Analyze large mutations 
sets and / or associate 
mutations with other 
classes of biomarkers 
(e.g. proteins) 
[29] 
Lack of standardized 
pre-analytical handling 
protocols, sample 
degradation,poor 
reproducibility 
Layout of standardization 
guidelines 
Automated purification / 
analysis chips minimizing 
sample handling 
[30] 
 
[5] 
Circulating Tumor 
Cells (CTCs) 
Poor efficiency of 
isolation from blood 
because of marker 
rarity, fragility, physical 
and phenotypic 
heterogeneity 
Combined use of 
different methodologies 
for enrichment / isolation 
(e.g. CellSearch + 
Parsortix) 
[121] 
Extracellular Vesicles 
(EV) 
High variability between 
isolation techniques – 
lack of standardized 
protocols 
Comprehensive 
standardization 
guidelines (e.g. MISEV 
2018) 
Automated purification / 
analysis chips (e.g. ACE 
Chips) 
[54] 
 
 
[59] 
Lack of single-EV protein 
expression analysis 
techniques (especially 
for exosomes) 
Development of high-
resolution flow 
cytometers 
Fluorescence-based 
Nanoparticle Tracking 
Analysis 
[6] 
 
[65] 
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Circulating Tumor 
RNAs (ctRNAs) 
Pre-analytical handling 
variability,RNA 
instability 
Layout of sample 
handling standardization 
guidelines  
Automated purification / 
analysis chips minimizing 
sample handling 
[85] 
 
[87] 
Abbreviations used:- ACE: Alternating Current Electrokinetic; MAF: Mutant Allele Fraction; 504 
MISEV: Minimal Information for Studies of Extracellular Vesicles, ACE: 505 
  506 
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GLOSSARY: 507 
Allele: variant form of a given gene 508 
BEAMing; Beads, Emulsion, Amplification, Magnetics, highly sensitive dPCR method which 509 
combines emulsion PCR and flow cytometry to identify and quantify DNA mutations 510 
CA 19-9,: Cancer Antigen 19-9. It is a portion of the Sialyl-Lewis A antigen. Its presence is 511 
highly correlated with advanced epithelial cancers. 512 
Clonal hematopoiesis, the condition in which a substantial proportion of mature blood cells 513 
is derived from a single dominant hematopoietic stem cell lineage. Clonal hematopoiesis has 514 
been linked to a greater than 10-fold increased risk of developing a hmtological  515 
cancerhematological cancer 516 
CAPP-Seq; Cancer Personalized Profiling by deep Sequencing, a sensitive method of analysis 517 
consisting of the sequencing of cancer-specific (personalized) panels of genes to identify 518 
cancer-specific mutations 519 
Companion diagnostic: , medical device, often an in vitro test, providing information that is 520 
essential and required for the safe and effective use of a corresponding drug. It is often 521 
developed simultaneously with the corresponding drug.  The cobas® EGFR Mutation Test v2 522 
described in the text, for example, consists of a PCR-based analysis of a set of mutations, 523 
insertions and deletions on the EGFR gene and is used to inform on the use of erlotinib and 524 
osimertinib in NSCLC 525 
DAPI:, 4′,6-diamidino-2-phenylindole. It is aA fluorescent dye that binds to AT-rich regions on 526 
DNA and is used to stain nuclei. 527 
Commented [MK(54]: Please remove the common terms 
that I highlight below as “not needed” and also un-bold them 
in the main text. Thank you. 
Commented [GDR55R54]: done 
Commented [MK(56]: Please give example of a common 
companion diagnostic…. 
Commented [GDR57R56]: done 
Page 31 of 43 
 
dPCR; Digital PCR, a biotechnolgical improvement of conventional PCR in whic each DNA fragment isamplifed in a separted reaction after sgregation of the single fragments hrough difernt aproaches. This alows an absolute quantifcation of the number of cpies of a detrminate gene or varition therof, whic ismore liable compared to the rlative quantifcation obtained by conventional PCR (whic requires the construction of a tirtion curve) a quantiative PCR method that isused for the absolute quantifcation of 528 
DNA, without the need of a calibration curve with samples of known quantities. In dPCR, the 529 
initial sample mix (which is prepared like a common qPCR) is split into several individual wells 530 
before the amplification step. Following PCR amplification, the absolute quantification of the 531 
target is calculated using Poisson statistics, based on the number of positive and negative 532 
wells for the target sequence. 533 
ddPCR; Droplet Digital PCR, a variation of dPCR in which the sample is partitioned in a large 534 
number of tiny water-oil emulsion droplets, containing on average one fragment of starting 535 
material each, before the analysis. The partition of the sample in small droplets in emulsion 536 
has the advantage, compared to dPCR, to increase the number of partitions analyzed and, 537 
therefore, the resolution of the analysis 538 
EMT, Epithelial-to-Mesenchymal Transition: a process in which epithelial cells lose their 539 
polarization and adhesion properties, gaining migratory properties and thus differentiating in 540 
mesenchymal cells. 541 
Genetic Heterogeneity: the presenceof different genetic clones, within the same tumor 542 
GFP: Green Fluorescent Protein 543 
Intravasation:, the process by which cancer cells invade blood or lymphatic vessels through 544 
the basal membrane 545 
hTERT: human Telomerase Reverse Transcriptase: the catalytic subunit of the Telomerase 546 
Complex 547 
LDT:; Laboratory-Developed Test, a type of in vitro diagnostic test that is designed, 548 
manufactured and used within a single laboratory 549 
Page 32 of 43 
 
Loci: (plural of locus) particular positions of genes on a chromosome 550 
serum concentration of a protein) in the same patient over a period of time. 551 
Methylation: transfer of a methyl (-CH3) group on a molecule 552 
Necrosis: , traumatic cell death resulting from acute cellular injury 553 
Next-Generation Sequencing: high-throughput DNA sequencing technologies 554 
PSO; Particle-Swarm Optimization, is a population based stochastic optimization technique 555 
that  shares many similarities with Genetic Algorithms.  556 
 557 
PCR: Polymerase Chain Reaction: technique used to amplify (increase the number of copies 558 
of) a specific DNA sequence 559 
Sensitivity: , proportion of positive individual/samples correctly identified as positivein a 560 
binary classification test (positive/negative; healthy/diseased) the sensitivity measures the 561 
proportion of actual positives that are correctly identified as positive by the test. It is also 562 
called true positive rate (TPR) 563 
Specificity: in a binary classification test, the specificity measures the proportion of actual 564 
negatives that are correctly identified as negative by the test. It is also called true negative 565 
rate (TNR)proportion of negative individual/samples correctly identified as negative 566 
WES; Whole Exome Sequencing, a genomic technique used for sequencing all the protein-567 
coding genes in a genome (exome) 568 
  569 
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Figure Legend: 863 
Figure 1, Key Figure– Components of the Tumor Circulome 864 
The Tumor Circulome comprises all the tumor-derived elements circulating in the 865 
bloodstream that can be used, directly or indirectly, as a source of cancer biomarkers. It 866 
includes circulating tumor proteins, TEPs, ctDNA, tumor-derived EVs, CTCs, tumor-derived EVs 867 
and their constituents, and ctRNAs and TEPs.  Each of these components has provide one or 868 
more levels of information. 869 
 The measurement of the concentration of single proteins or panels composed of multiple 870 
tumor proteins is the current gold standard used in cancer management.  for relapse 871 
detection. As single proteins may not be totally informative, the use of panels of proteins is a 872 
current trend. The information detectable from ctDNA include;s mutations, deletions, gene 873 
amplifications, methylation patterns and translocations. CTCs provide a rich source of  874 
genomic, proteomic, transcriptomic and cytogenetic information and can be cultured ex vivo 875 
to perform personalized drug sensitivity testing The The ex vivo culture of CTCs allows 876 
clinicians to perform personalized drug sensitivity tests to help in the treatment decision-877 
making process.  constituents  of Extracellular Vesicles (EV) provides a “molecular fingerprint” 878 
of the tumor cells of origin, and their DNA , RNA and protein (both surface and intraluminal) 879 
content provides a rich source of  cancer biomarkers. ctRNA, including EV-associated 880 
circulating RNA, includes different RNA classes. Among these, miRNA expression panels and 881 
lncRNA expression are good sources of quantitative biomarker information. Furthermore, 882 
qQualitative information such as the presence of tumor-specific alternatively spliced 883 
transcripts and gene fusion transcriptsalternative splicing and gene fusions can also be 884 
obtained from this source. The platelets of cancer patients or tumor educated platelets (TEPs) 885 
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are also source of biomarker information,  containing tumor-derived RNAs, generating 886 
specific platelet cancer signatures, and tumor-induced alternatively spliced transcripts. 887 
Abbreviations used- CTC: Circulating Tumor Cells; ctDNA: circulating tumor DNA; ctRNA: 888 
circulating tumor RNA; EV: Extracellular vesicle; lncRNA: long non-coding RNA; miRNA: 889 
microRNA; mRNA: messenger RNA; nc RNA: non-coding RNA; TEP: tumor-educated platelet. 890 
 891 
 892 
